fbpx

According to an article published in Forbes, despite the fact that investors spent hundreds of millions of dollars into Axovant and its experimental Alzheimer’s drug, intepirdine,  the medication was found to be no different from 99 percent of medicines tested against Alzheimer’s since 2002.

Read more here